Sinopharm Group Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 5/6
Sinopharm Group kazançlarla iyi bir şekilde karşılanan, 4.49% cari getiriye sahip, temettü ödeyen bir şirkettir.
Anahtar bilgiler
4.5%
Temettü verimi
0.02%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 4.5% |
| Gelecekteki Temettü Verimi | 4.8% |
| Temettü Büyümesi | 14.3% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | HK$0.956 |
| Ödeme oranı | 31% |
Son temettü ve geri alım güncellemeleri
Recent updates
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 1099 şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.
Büyüyen Temettü: 1099 şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.
Piyasaya Karşı Temettü Getirisi
| Sinopharm Group Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (1099) | 4.5% |
| Pazarın Alt %25'i (HK) | 3.3% |
| Pazarın En İyi %25'i (HK) | 8.1% |
| Sektör Ortalaması (Healthcare) | 4.1% |
| Analist tahmini (1099) (3 yıla kadar) | 4.8% |
Önemli Temettü: 1099 'in temettüsü ( 4.49% ), Hong Kong piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 3.3% ) daha yüksektir.
Yüksek Temettü: 1099 'in temettüsü ( 4.49% ), Hong Kong piyasasındaki temettü ödeyenlerin en üst %25'ine ( 8.06% ) kıyasla düşüktür.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 31.3% ) ile 1099 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Düşük nakit ödeme oranı ( 16% ) sayesinde 1099 'un temettü ödemeleri nakit akışları tarafından iyi bir şekilde karşılanmaktadır.